Aysen Topalkara

Turkish Journal of Ophthalmology

We evaluated the efficacy of Zaraccom F260 intraocular lenses (IOL) on cataract treatment in 97 adult cataract patients (114 eyes) who underwent phacoemulsification and IOL implantation. The mean preoperative best-corrected visual acuity (BCVA) was 0.26 +/- 0.26 at one week 0.49 +/- 0.25 and 0.9 +/- 0.28 at follow-ups. The Zaraccom F 260 is an alternative for the patients requiring lens replacement.

Purpose: The aim of this study was to investigate the in vitro effects of an ethanolic extract of propolis on the growth and adherence of Acanthamoeba castellanii trophozoites and cysts. Methods: The effect of propolis with concentrations of 8.0, 6.0, 5.0, 4.0, 3.0, and 2.0 mg/mL on the proliferation of A. castellanii trophozoites, and with a concentration of 62.25, 31.25, 15.62, 7.81, 3.90, 1.95, and 0.97 mg/mL on the proliferation of A. castellanii cysts, at 1, 3, 6, 12, 24, 48, and 72 h were examined in vitro. Results: After 1–72 h, incubation in concentrations between 2.0 and 6.0 mg/mL, its effect was amoebistatic; at concentrations of 8.0 mg/mL and higher, its effect was amoebicidal. After 48 h or longer incubation times at 15.62 mg/mL and at higher concentrations, the propolis extract was cysticidal. At concentrations of 1.97 mg/mL or lower, there was no observable effect at any time point. Conclusions: These findings indicate that ethanolic extract of propolis has amoebicidal, as well as cysticidal, properties for Acanthamoeba trophozoites and cysts. Propolis alone, or in combination with other amoebicidal agents, may be used in clinical practice after further investigations.

The purpose of this study is to investigate the histopathological changes of ropivacaine on intraocular tissues after intravitreal and anterior chamber injection. Methods: Thirty Wistar albino rats were randomly divided into three groups; each group consisted of 10 rats. Group 1 was injected intravitreal 0.05 mL (0.25 mg) ropivacaine. Group 2 was injected anterior chamber 0.02 mL (0.1 mg) ropivacaine. Group 3 was used as control five were injected intravitreal 0.05 mL balanced salt solutions (BSS®), and the other five rats were injected anterior chamber 0.02 mL BSS. On postinjection days 2, 5, 7, 10 and 15, the eyes were enucleated, and iris, ciliary body, and retina were processed for light microscopic examination. Histologic sections were stained with hematoxylin-eosin, periodic acid-Schiff, and Masson trichrome stains. In additional, the corneal thickness was measured with objective micrometer. Results: Histopathological examination revealed no abnormalities in all eyes after 2, 5, 7, 10, and 15 days in the study and control groups. Similar findings in the iris, ciliary body, and retina were observed. Histologic sections did not reveal inflammatory reaction, cell degeneration, and cell necrosis. Mean corneal thickness of group 2 was 249.5±36.5 μm and group 3 (0.02 mL BSS injected anterior chamber, five rats) was 248.6±25.3 μm. There was no statistically significant difference between groups for corneal thickness (p > 0.05). Conclusion: Our findings have shown that ropivacaine appeared to be safe, with no histopathological abnormalities with intravitreal and anterior chamber injection.